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PPRECLINICAL STUDY
Percutaneous Cardiac Recirculation-Mediated Gene
Transfer of an Inhibitory Phospholamban Peptide
Reverses Advanced Heart Failure in Large Animals
David M. Kaye, MD, PHD,* Arthur Preovolos, BS,* Tanneale Marshall, BS,* Melissa Byrne, PHD,*
Masahiko Hoshijima, PHD,† Roger Hajjar, MD,‡ Justin A. Mariani, MD,* Salvatore Pepe, PHD,*
Kenneth R. Chien, MD, PHD,‡ John M. Power, PHD*
Melbourne, Australia; La Jolla, California; and Boston, Massachusetts
Objectives The purpose of this study was to develop a clinically applicable high-efficiency percutaneous means of therapeu-
tic gene delivery to the failing heart.
Background Substantial advances in the understanding of the cellular and molecular basis of heart failure (HF) have recently
fostered interest in the potential utility of gene and cell therapy as novel therapeutic approaches. However, suc-
cessful clinical translation is currently limited by the lack of safe, efficient, and selective delivery systems.
Methods We developed a novel percutaneous closed-loop recirculatory system that provides homogeneous myocardial
delivery for gene transfer in the failing large animal heart. After 4 weeks’ rapid pacing in adult sheep to induce
HF, the animals were randomly allocated to receive either adenovirus expressing a pseudophosphorylated mu-
tant (AdS16E) of phospholamban (PLN) or Ad–-galactosidase (AdLacZ).
Results Two weeks after gene delivery, in the presence of continued pacing, left ventricular (LV) ejection fraction had
significantly improved in the AdS16E-treated animals (27  3% to 50  4%; p  0.001), whereas a further de-
cline occurred in the AdLacZ group (34  4% to 27  3%; p  0.05). In conjunction, AdS16E delivery resulted in
significant reductions in LV filling pressures and end-diastolic diameter (both p  0.05). In conjunction, AdS16E-
treated animals showed significant improvement in the expression of PLN and Ca2-adenosine triphosphatase
activity. In separate animals, recirculating AdLacZ delivery was shown to achieve superior myocardial gene ex-
pression in contrast to intracoronary delivery and was associated with lower systemic expression.
Conclusions We report the development of a novel closed-loop system for cardiac gene therapy. Using this approach delivery
of AdS16E reversed HF progression in a large animal HF model. (J Am Coll Cardiol 2007;50:253–60) © 2007
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.047d
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she development of new technology for the local organ-
estricted delivery of molecular-based therapeutic agents
ould represent a major advance in the design of biologi-
ally targeted therapy by achieving satisfactory local concen-
rations without the potential for systemic toxicity. Toward
his end, the convergence of device technology and biologic
herapy has recently become a major focus for research and
rom the *Baker Heart Research Institute, Melbourne, Australia; †Institute of
olecular Medicine, University of California–San Diego, La Jolla, California; and
he ‡Massachusetts General Hospital, Cardiovascular Research Center, Harvard
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Manuscript received December 4, 2006; revised manuscript received March 22,
007, accepted March 28, 2007.evelopment in the translational area. For example, the
evelopment of drug-eluting stents for the prevention of
ascular restenosis represents a prime example of the combi-
ation of a drug with a device, in this case to selectively inhibit
he proliferation of intimal cells within the device itself.
Although some disease paradigms may require very lo-
alized delivery, other disease processes may require more
omogeneous high-efficiency delivery to specific organs.
eart failure (HF) is a common clinical cardiovascular
isorder, characterized by complex pathophysiology and by
ubstantial morbidity and mortality. While the key under-
ying mechanism in HF is contractile failure of the myocar-
ium, the only currently available pharmacotherapeutic
trategies that prolong life are somewhat indirectly acting
gents, in particular directed at the sympathetic nervous
ystem and renin-angiotensin system (1). Thus, although
he cellular and molecular causes of myocardial failure are
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Recirculation-Based Cardiac Gene Transfer July 17, 2007:253–60well understood, current thera-
pies do not directly target these
disorders. Accordingly, in HF
there is a substantial interest in
the potential role of gene therapy
or in therapies that control gene
expression as a therapeutic tool
in the treatment of HF, given
that the extensive identification
of the molecular deficiencies of
the failing heart provides a logi-
cal basis for the application of
specific gene therapy (2–4).
In particular, in HF an exten-
sive body of data indicate that
key defects in the regulation of
intracellular Ca2 play a pivotal
role in the development and pro-
ression of contractile failure. In both experimental models
nd clinical heart failure, it has been reported that expres-
ion and activity of the sarcoplasmic reticulum Ca2-
denosine triphosphatase (ATPase) type 2 (SERCA2) is
arkedly reduced, typically in conjunction with an increase
n the expression and the activity of the regulatory protein
hospholamban (PLN) (5–7). Together, these defects pro-
ide a clear molecular basis for the observations of reduced
arcoplasmic reticulum (SR) Ca2 release and diastolic
a2 overload in cardiomyocytes from failing myocardium
8,9). In support of these observations, studies performed in
ransgenic animals or by using gene-transfer strategies in
mall animals confirm the role of these molecular defects in
ausing myocardial failure (10,11).
The major current limitation for the clinical translation of
ene therapy in HF is the development of suitable delivery
ools (12,13). Preferably, an ideal delivery mechanism would
rovide safe, homogeneous myocardial delivery with limited
ystemic “spillover” or expression and would require as little
elivery vector as possible. In the present study, we report
he therapeutic delivery of an adenoviral vector encompass-
ng a pseudophosphorylated mutant of PLN, using a novel
losed-loop percutaneous catheter-based recirculating car-
iac perfusion system in large animals with HF.
ethods
ecirculating delivery of myocardial perfusate and detec-
ion of viral distribution through fluorescent imaging. Re-
irculating perfusate delivery was achieved with the use of a
ovel cardiac perfusion circuit. Under fluoroscopic guid-
nce, coronary venous blood was recaptured from the
oronary sinus with the use of a percutaneously positioned
cclusive balloon recovery catheter. The draining catheter
as placed in such a position to exclude the azygous vein,
ither by occluding it with the balloon or beyond the entry
oint of the azygous vein. Further, the recovery catheter
Abbreviations
and Acronyms
Ad  adenovirus
HF  heart failure
LacZ  -galactosidase
LVEF  left ventricular
ejection fraction
PLN  phospholamban
S16EPLN  serine-to-
glutamate “pseudo-
phosphorylated”
phospholamban mutant
SERCA  sarcoplasmic
reticulum Ca2-ATPase
SR  sarcoplasmic
reticulumncorporated a structural element to prevent dynamic col- Sapse during the application of suction (VFocus, VKardia
nc., Minneapolis, Minnesota). Venous return was facili-
ated by the use of a roller pump, followed by reoxygenation
sing an oxygenator membrane. Oxygenated perfusate was
hen directed to the left coronary territory via a nonocclusive
atheter placed percutaneously in the left main coronary
rtery. Right coronary artery cannulation was not performed,
iven that in the sheep this vessel is generally small, with a
imited myocardial distribution. Optimization of pump flow is
etermined by progressively increasing the roller pump speed
o achieve a pump head pressure of 80 to 100 mm Hg on
he venous side, which we demonstrated as corresponding to a
oronary sinus pressure of 0 to 5 mm Hg. At the conclusion of
he recirculation period, blood continued to be removed from
he coronary sinus for an additional 2 min and this, together
ith the remaining circuit blood, was discarded to avoid
ystemic delivery of residual perfusate.
To determine the distribution of myocardial perfusate de-
ivered in this manner we characterized the pattern of delivery
f the fluorophore indocyanine green (ICG). Ten milliliters of
CG (2 mg/ml; Akorn, Decatur, Illinois) was injected into the
ircuit and recirculated for 10 min. Hearts were then explanted
nd examined using near-infrared spectroscopy (NIRS). Spec-
roscopic images were acquired as described in detail previously
14).
nimal procedures and gene delivery. Heart failure was
nduced in sheep by rapid ventricular pacing (180 beats/min)
or a period of 4 weeks, as previously described (15). On the
ay of gene transfer and on the final study day, echocardio-
raphic (Cypress, Acuson, Malvern, Pennsylvania) and left
entricular hemodynamic assessments (Millar catheter) were
erformed 1 h after rapid pacing was stopped. For gene
elivery, animals were randomized to receive either adenoviral
erine-to-glutamate “pseudophosphorylated” PLN mutant
AdS16EPLN; 1  1012 vp; n  9) or adenoviral
-galactosidase (AdLacZ; 1 1012 vp; n 6), delivered in the
ntegrade recirculating mode as described in the preceding
ection. Both vectors were driven by a cytomegalovirus
romoter and the AdLacZ was non-nuclear localizing.
epeat hemodynamic and echocardiographic assessment
as performed 2 weeks after gene transfer. At the conclu-
ion of the studies, left ventricular samples were collected,
apidly frozen in liquid nitrogen and stored at 80°C for
ubsequent molecular, biologic, and biochemical analysis. In
separate cohort of normal animals, we compared the
yocardial, pulmonary, and hepatic expression of
-galactosidase after intracoronary (n 3) and recirculating
n  3) delivery of AdLacZ (1  1012 vp). All animal
tudies were performed with the approval of the Institu-
ional Ethics Review Committee.
istology and immunohistochemistry. For histology,
araffin-embedded sections were stained with hematoxylin
nd eosin and examined under light microscopy. For
-galactosidase immunohistochemistry, sections were
eparaffinized in histolene and rehydrated with ethanol.
ections were then washed in 1% H2O2 to block endoge-
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July 17, 2007:253–60 Recirculation-Based Cardiac Gene Transferous peroxidase activity. After brief rinsing, nonspecific
ntibody binding was suppressed by 1% normal goat serum
iluted in Tris-buffered saline (TBS; 10 mmol/l Tris-HCl,
H 7.6, 150 mmol/l NaCl) with 1% bovine serum albumin
BSA). Sections were then incubated with rabbit anti–-
alactosidase antibody (Abcam, Cambridge, United King-
om) diluted 1:1,500 in TBS with 1% BSA and 0.1%
ween overnight at 4°C. After rinsing in TBS the sections
ere incubated with horseradish peroxidase-conjugated goat
ntirabbit antibody (BioRad) diluted 1:250 in TBS with 0.1%
ween for 1 h at room temperature. After several rinsings, the
ound antibody was visualized using 3,3=-diaminobenzidine
etrahydrochloride as chromogen. Control sections incubated
ithout the primary antibody, as well as sections from non-
reated animals, showed very low background.
olecular and biochemical analyses. Expression of PLN
nd phospho (S16) PLN was analyzed by Western blot
nalysis using commercially available antibodies (Affinity
ioreagents, Golden, Colorado; and Abcam). For the de-
ermination of myocardial SERCA activity, samples were
ulverized in liquid nitrogen, and Ca2-dependent ATPase
ctivity was determined using a pyruvate-nicotinamide ad-
nine dinucleotide 3-step coupled reaction (16). Free Ca2
as determined as previously described (17,18). Assays were
un in quadruplicate, and conditions were validated in
ndependent reactions using the mycotoxin cyclopiazonic
cid (10 mol/l) to inhibit SR Ca2-ATPase (19), butane-
ione monoxime (30 mmol/l) to inhibit potential residual
evels of Ca2-dependent actomyosin ATPase, and EGTA
4 mmol/l) to determine basal ATPase activity.
tatistics. Data are presented as mean  SEM. Between-
roup comparisons were performed using an unpaired t test
or normally distributed data or a Mann-Whitney test for
ata that were not normally distributed (as assessed by the
olmogorov-Smirnov test). Within-group comparisons
ere performed using a paired t test as appropriate. A p
alue 0.05 was considered to be statistically significant.
esults
stablishment of recirculating perfusate delivery to the
eart. We developed a novel recirculating technique for the
elective percutaneous delivery of gene therapy to the failing
eart. As shown in Figures 1A and 1B, the coronary sinus is
electively cannulated with a balloon drainage catheter system
hat incorporates a retractable nitinol device which maintains
enous patency during coronary sinus drainage. This venous
ecovery system is connected to an extracorporeal pump-
xygenator circuit, with return to the myocardium via a
ercutaneously placed left coronary arterial catheter for ante-
rade perfusate delivery. To demonstrate the homogeneity of
erfusion, the pattern of distribution of indocyanine green
hroughout the myocardium was examined using near-infrared
pectroscopy. After 10 min of recirculation, a homogeneous
ransmural pattern of perfusate delivery was evident in a
egional pattern consistent with the perfusion territory of the geft coronary arteries (Fig. 2). In conjunction, there was no
ignificant accumulation of lactate within the circuit blood
uring this period (baseline vs. 10 min: 2.9  0.8 mmol/l vs.
.1  0.6 mmol/l; p  NS), and circuit blood oxygen
aturation was maintained at 100% throughout the procedure.
he combined application of a recirculating approach to
yocardial perfusion with adenoviral delivery showed no
istologic evidence of myocardial inflammation or infarction
Fig. 3).
To evaluate the relative efficacy of this novel approach over
ntracoronary gene delivery, we examined the intensity of
yocardial -galactosidase expression in the myocardium by
mmunohistochemistry. In preliminary studies we compared
yocardial expression of -galactosidase after delivery of 1010
ersus 1012 vp AdLacZ. Delivery of the lower amount resulted
n minimal or undetectable levels (data not shown). Accord-
ngly, delivery of adenovirus in the range of 1012 vp was
ubsequently used. Subsequently, we compared intracoronary
n  3) with recirculating delivery (n  3) of 1  1012 vp
dLacZ in normal sheep. These studies visually indicated
Figure 1 Percutaneous Approach to
Recirculating Cardiac Gene Delivery
(A) Diagram demonstrates the position of catheters placed within the
heart. (B) Circuit diagram for recirculating gene delivery to the myocardium.
V  viral vector.reater LacZ expression in animals treated with recirculating
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Recirculation-Based Cardiac Gene Transfer July 17, 2007:253–60ene delivery. In conjunction, we attempted to quantify
-galactosidase enzymatic activity in myocardial tissue sam-
les. However, we were not able to distinguish activity distinct
Figure 2 Perfusate Distribution Pattern Following Cardiac Reci
Pattern of distribution of indocyanine green through the myocardium during recircu
right panels  cross section). Images show a clear demarcation between perfuse
coronary artery distribution.
Figure 3 Myocardial Pattern of Gene
Expression Following Recirculating Delivery
(A) Hematoxylin and eosin-stained section of nonfailing myocardium 2 weeks
after cardiac adenovirus -galactosidase (AdLacZ) recirculation, without evi-
dence of inflammation or ischemic damage. (B and C) Immunohistochemical
sections of nonfailing myocardium stained for -galactosidase 2 weeks after
direct intracoronary (B) and recirculating (C) delivery of AdLacZ.rom that in control samples, possibly owing to the influence of
ndogenous -galactosidase as has been previously reported
20). Next, we also determined the capacity of the recirculation
ystem to limit the systemic leakage of adenovirus by investi-
ating the expression of -galactosidase in the liver and lungs.
tion
as determined by near-infrared spectroscopy (left panels  anterior view;
nonperfused regions, the latter corresponding with the nonperfused right
Figure 4 Delivery Mode Determines the Extent
of Extracardiac Transgene Expression
Immunohistochemical sections of lung stained for -galactosidase 2 weeks after
direct intracoronary (A) and recirculating (B) delivery of adenovirus -galactosidase
(AdLacZ). Immunohistochemical sections of liver stained for -galactosidase after
direct intracoronary (C) and recirculating (D) delivery of AdLacZ.rcula
lation,
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July 17, 2007:253–60 Recirculation-Based Cardiac Gene Transfers shown in Figure 4, the use of the recirculating approach
ielded a higher intensity of -galactosidase expression in the
yocardium and lower expression in the liver and lungs.
otably, during direct intracoronary infusion of AdLacZ there
as some evidence of alveolar infiltration consistent with
revious reports (21).
chocardiographic, hemodynamic, and molecular effects
f recirculating S16EPLN delivery. To evaluate the ther-
peutic potential of percutaneous recirculating gene delivery
n the failing myocardium, we compared the effects of
elivery of AdLacZ to those of AdS16EPLN in sheep with
acing-induced HF. Four weeks after the commencement
f rapid ventricular pacing, echocardiographic and hemody-
amic evaluation demonstrated the presence of significant
entricular dysfunction. Before gene delivery, the group
ean left ventricular ejection fraction (LVEF) was 29 2%
nd the group mean left ventricular end-diastolic pressure
as 24  3 mm Hg (n  15). Despite a further 2 weeks’
apid ventricular pacing, animals treated with AdS16EPLN
howed significant hemodynamic improvement in conjunc-
ion with reverse ventricular remodeling, whereas animals
reated with AdLacZ demonstrated progressive ventricular
ailure, as indicated in Figure 5. Specifically, in the AdLacZ
nimals there was a continued reduction in LVEF from 35 
% to 27  3% (p  0.05), whereas in the AdS16EPLN
Figure 5 Hemodynamic Effect of S16E Gene Delivery on the Fa
Echocardiographic and hemodynamic effects of AdS16EPLN (n  9) gene transfer to t
tricular (LV) ejection fraction; (B) LV end-diastolic area; (C) LV end-diastolic pressure (
after gene delivery. AdLacZ  adenovirus -galactosidase; AdS16EPLN  adenovirusnimals the LVEF increased from 27  3% to 50  9% 1p  0.001). Consistent with the induction of a process of
everse remodeling, the left ventricular end-diastolic area
ell significantly in AdS16EPLN-treated sheep (37.5  1.7
m2 to 32.4  1.7 cm2; p  0.01), whereas a continued
ncrease in the left ventricular end-diastolic area was ob-
erved in the AdLacZ-treated animals (36.2  2.6 cm2 to
1.3  2.0 cm2; p  0.01). Measures of diastolic function
lso appeared to be favorably affected by AdS16EPLN
elivery. In treated animals, the left ventricular end-diastolic
ressure fell from 26.3 2.6 mm Hg to 19.9 1.8 mm Hg
p  0.05), whereas it remained unchanged in the AdLacZ
roup (Fig. 5). Directionally similar changes also occurred
n the peak dP/dt (AdLacZ: 1,957  219 mm Hg/s to
1,562  206 mm Hg/s; p  0.09; AdS16EPLN:
1,572  166 mm Hg/s to 1,671  116 mm Hg/s; p 
S) and in the time constant of relaxation, tau (AdLacZ:
9.2  2.4 ms to 41.8  3.5 ms; p  NS; AdS16EPLN:
7.6  1.4 ms to 41.8  3.3 ms; p  NS). In animals
eceiving AdS16EPLN, the heart rate did not significantly
hange with gene delivery (64  2 beats/min to 69  3
eats/min). The AdLacZ-treated animals had a signifi-
antly higher baseline heart rate (p  0.05), driven by 2
nimals with a significant resting tachycardia; however,
dLacZ delivery did not significantly alter heart rate (95 
Heart
ing ovine heart compared with AdLacZ (lacZ) (n  6) treated animals. (A) Left ven-
D) Peak positive dP/dt. Solid bars  before gene delivery; open bars  2 weeks
to-glutamate “pseudo-phosphorylated” phospholamban mutant.iling
he fail
EDP); (
serine-3 beats/min to 78  9 beats/min).
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Recirculation-Based Cardiac Gene Transfer July 17, 2007:253–60To determine the molecular basis for the functional
mprovement in animals that underwent AdS16EPLN gene
ransfer, we measured the expression of total and phosphor-
lated (S16) PLN by immunoblotting and SERCA activity.
s illustrated in Figure 6, immunoblot analysis demon-
trated an increase in the abundance of phospho-PLN in
16E-treated animals, and, consistent with this finding,
ERCA activity was significantly increased in S16EPLN
F animals compared with those treated with AdLacZ
Fig. 7).
iscussion
ver the past decade, exponential growth in the molecular
haracterization of HF has led to the identification of a
rowing number of targets for disease modification. How-
ver, many of these are proteins that play critical roles in
ignaling in other organ systems and would require restrict-
ng their expression to the heart in vivo. In the case of HF,
he rapid identification of a myriad of molecular targets also
resents the same underlying issues in the quest to translate
esearch into the development of a therapeutic tool. For HF,
any of the most appropriate targets are intracellular
Figure 6 Effect of S16E Gene Delivery
on Phospholamban Expression
(A) Western blots showing expression of total and phospho-phospholamban
(pPLN) in nonfailing and failing myocardium (after AdLacZ and AdS16EPLN).
(B) Bar graphs demonstrating the pPLN:total phospholamban (tPLN) ratio in
control nonfailing (n  4) and heart failure (HF) AdLacZ (n  4) and AdS16E
(n  5) treated animals. *p  0.05 versus control; ^p  0.05 versus HF-
AdLacZ. Abbreviations as in Figure 5.roteins involved in the regulation of intracellular calciumnd/or involvement in signaling (4). Accordingly, manipu-
ation of the expression of these proteins is likely best
ddressed by a gene therapy-based approach, which for safe
nd effective translation into clinical practice requires the
onjunction of several key elements. These include the use
f a high-efficiency viral vector that has the capacity to
ncorporate an appropriate therapeutic gene.
Defective cellular Ca2 handling, particularly that medi-
ted by the sarcoplasmic reticulum, is a well recognized
eature of HF. This phenomenon has been reported in both
linical and experimental HF and has been variously attrib-
ted to a reduction in the expression of SERCA protein or
ts activity (6,22). Alterations in the amount or activity of
ERCA have been shown to significantly influence the rate
nd amplitude of myocardial contraction as well as the rate
nd extent of relaxation (23). In further support of this
otion, SERCA2a gene transfer has been shown to improve
oth systolic and diastolic function and survival in experi-
ental HF models (24,25). In conjunction with the central
ole of SERCA in the pathophysiology of HF, the regula-
ory protein PLN is also pivotal, given its role as a major
egulator of SERCA activity. In the nonphosphorylated
tate, PLN inhibits SERCA activity, whereas when it
ndergoes phosphorylation this negative regulation is re-
ieved. As such, many studies have shown that PLN is a
ajor determinant of cardiac contractility and of the myo-
ardial response to -adrenoceptor agonists (26). Given the
mportant role of PLN as a regulator of SERCA, particular
mphasis has also been placed upon the influence of the
atio of PLN to SERCA myocardial contractility (27).
In conjunction with altered SERCA expression, disordered
LN expression per se has also been suggested to possibly play
role in HF, although this remains controversial. In particular,
t has been shown that PLN is relatively hypophosphorylated
n HF, which contributes to the reduction in SERCA activity
Figure 7 Effect of S16E Gene Delivery on SERCA Activity
Sarcoplasmic reticulum Ca2-adenosine triphosphatase (ATPase) (SERCA)
activity in control nonfailing (n  3) and heart failure (HF) AdLacZ (n  4) and
AdS16E (n  4) treated animals. Abbreviations as in Figure 5.
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July 17, 2007:253–60 Recirculation-Based Cardiac Gene Transfer28). Evidence also exists to indicate that PLN expression
aries across the left ventricular wall in HF, although the
recise impact of this heterogeneous pattern of expression on
entricular function is not clear (29). Consequently, several
trategies to reduce the expression of PLN have been shown to
mprove myocardial contractility (30–32), although these find-
ngs are not consistent (33). Furthermore, several mutations of
LN, resulting in either complete ablation or alterations in the
rotein structure, have been accompanied by cardiomyopathy
n man (34,35).
In the context of HF, myocardial gene delivery requires a
afe well tolerated delivery tool that provides homogeneous
issue distribution. Preferably, such an approach would also
void the potential adverse effects of systemic leakage with its
ttendant risk of systemic gene expression and an immune
esponse to the viral capsid (36,37). Although many attempts
ave been made to develop techniques for somatic gene
ransfer in HF, many are inefficient. Current techniques with
ossible relevance to HF in particular range from simple
ntracoronary injection, to coronary sinus retroperfusion and
yocardial perfusion during cardiopulmonary bypass. Al-
hough direct single bolus intracoronary injection may be the
implest approach, its limitations include the need for coad-
inistration of potentially toxic adjuvant agents and an inher-
nt inability to prevent systemic leakage of the delivery vector
13,38,39). Coronary sinus retroperfusion (40) has been shown
o provide some myocardial gene delivery; however, it has not
een evaluated in the context of HF. Of note, we have
reviously observed that balloon coronary sinus occlusion alone
auses a rapid rise in the coronary venous pressure (unpub-
ished observation), which would likely be poorly tolerated by
he failing heart. Gene delivery to the heart during full
ardiopulmonary bypass has also been reported (38), although
his approach would have limited application to a broader HF
opulation.
With these issues in mind, in the present study we
eveloped a percutaneous closed-loop system for myocardial
ene delivery which could be applied to the failing heart in
arge animals and ultimately in man. We hypothesized that
closed-loop recirculation system for myocardial gene
elivery might achieve several desirable features. First, by
voiding peripheral systemic delivery or even single-pass
ntracoronary infusion the concentration of vector reaching
he myocardium would be higher. In the present study we
howed that the expression of a reported gene was higher
uring recirculation compared with intracoronary delivery.
econd, we also aimed to reduce systemic delivery of vector
o avoid potential deleterious effects of transgene expression
n other organs. Indeed, in the present study we demon-
trated a reduction in the pulmonary and hepatic expression
f -galactosidase. In conjunction, we observed some pos-
ible evidence of lung inflammation following intracoronary
nfusion of AdLacZ, which was not evident with closed-
oop cardiac recirculation. From a practical clinical perspec-
ive, the application of this approach uses commonly per-
ormed cardiac catheterization techniques combined with ltandard blood perfusion methods commonly used in the
ardiothoracic and intensive care settings. In the present
tudy the recirculating approach was well tolerated in
nimals with evidence of moderate to severe HF.
On the basis of data suggesting that the restoration of
efective control of intracellular calcium homeostasis may
e beneficial in HF (5,12,25), we elected to deliver a
seudophosphorylated mutant of PLN, which has been
reviously shown to rescue the HF phenotype in small
nimals with HF (10). In the present study, we showed
hat the recirculating delivery of S16EPLN was able to
ignificantly improve indices of both systolic and diastolic
yocardial function in concert with a reversal of the
rocess of ventricular remodeling that typifies progressive
F. These observations are consistent with earlier studies
10).
Although in the present study we documented that
elivery of S16EPLN resulted in an increase in the ratio of
hospho-PLN to total PLN, we were not able to specifically
uantitate the relative abundance of endogenous phospho-
LN to S16EPLN, because of the lack of an antibody
pecific to S16EPLN. In the present study we elected to
easure SERCA activity rather than SERCA protein
xpression, given that activity per se rather than protein
evels contributes to myocardial function (27). In earlier
tudies, SERCA delivery has been shown to reduce the
requency of ventricular arrhythmias (41); however, in the
resent study we did not perform detailed electrophysiologic
esting or telemetric monitoring.
Going forward, the likely ultimate utility of adenoviral
ectors in the clinical setting is limited by their short
uration of expression, inflammatory potential, and low
ransduction efficiency. Additionally, the immunogenic
roperties of the encoded protein also play a significant role
n the ultimate level of expression. Accordingly, current
ttention is focused on the utility of recombinant adeno-
ssociated viruses (rAAV), which demonstrate higher effi-
iency and greater tissue specificity (36,42–44). Despite the
ttraction of rAAV as vectors for human gene therapy,
ranslation into the clinic also potentially remains limited.
lthough tissue specificity may be greater for specific rAAV
erotypes (36), recent studies indicate that inflammatory
esponses may significantly limit transgene expression and
licit significant target organ damage (45). Adeno-
ssociated virus gene expression is also increasingly under-
tood to be limited by the prevailing level of AAV antibod-
es (46). In addition, rAAV are substantially more complex
o generate in quantities likely required for clinical use if
elivered systemically, thereby limiting possible clinical
ranslation. Together, these potential limitations of AAV
pplication to somatic gene transfer will also require the
evelopment of an interventional approach for targeted
herapeutic delivery.
In conclusion, we report the development of a novel
nabling technology for the percutaneous delivery of mo-
ecular or cellular therapy to the failing human heart.
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